Inari Medical (NASDAQ:NARI) PT Lowered to $50.00 at Piper Sandler

Inari Medical (NASDAQ:NARI – Free Report) had its price objective decreased by Piper Sandler from $55.00 to $50.00 in a research note published on Wednesday, Benzinga reports. Piper Sandler currently has a neutral rating on the stock. Several other equities research analysts also recently commented on NARI. Needham & Company LLC decreased their price objective […]

Related Keywords

United States ,Piper Sandler ,Mitchc Hill ,Handelsinvest Investeringsforvaltning ,William Hoffman ,Inari Medical Inc ,Needham Company ,Fifth Third Bancorp ,Canaccord Genuity Group ,Third Bancorp ,Inari Medical Company Profile ,Nisa Investment Advisors ,Securities Exchange Commission ,Benjaminf Edwards Company Inc ,Inari Medical ,Free Report ,Truist Financial ,Moderate Buy ,Get Free Report ,Director William Hoffman ,Exchange Commission ,Management Fondsmaeglerselskab ,Investment Advisors ,Inari Medical Daily ,